Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures

Simulations Plus (SLP) is the subject of an investor securities-lawsuit investigation after fiscal 2025 guidance was cut from $90M–$93M to $76M–$80M, tied to customer budget reductions, project cancellations, and delays. The stock fell >24% after the June 11 preliminary results and nearly another 26% after the company reported a $67.3M net loss (including a $77.2M non-cash impairment) and disclosed the dismissal of Grant Thornton over unresolved accounting and internal control concerns. Overall, the disclosures signal deteriorating fundamentals and heightened reporting/oversight risk, likely pressuring the shares.

Analysis

This is less a one-off legal headline than a credibility reset for a small-cap, high-multiple tools vendor. When a company’s forecast gets cut and the cleanup comes with audit/internal-control noise, the market usually applies a persistent governance discount that outlives the initial drop; the real damage is to multiple durability, not just this year’s revenue. In that setup, even a modest miss can trigger further de-rating because investors stop underwriting management’s numbers at face value.

The second-order read-through is broader than SLP. If pharma/biotech budgets are truly rolling over, the pressure should spill into adjacent life-science software and drug-development names such as CERT and SDGR, but SLP is uniquely vulnerable because customer hesitation plus reporting uncertainty can slow bookings conversion and increase discounting. That combination tends to hurt cash conversion and working capital before it shows up in headline revenue, which matters more over the next 1-2 quarters than the impairment charge itself.

The catalyst path is auditor remediation, any restatement risk, and the next quarter of bookings commentary over the next 1-3 months. Contrarianly, if the accounting issue is mostly classification/reporting and the customer slowdown is cyclical rather than structural, the selloff may have overshot intrinsic value after the first two leg-downs. The thesis is falsified by a clean filing cycle, no further control findings, and evidence that pipeline recovery is real rather than accounting-driven.

Key Decisions for Investors

• Avoid fresh longs in SLP until the company clears its auditor/internal-control issues; for existing holders, reduce exposure on any relief rally and treat the next filing as the key catalyst window over 1-3 months.
• For event-driven accounts, use a short SLP position or put spread into the next earnings/update cycle; the risk/reward favors another 15-25% downside if there is any hint of restatement, guidance withdrawal, or delayed filing.
• Pair trade: long CERT / short SLP over 1-3 months to express the view that cleaner life-science software franchises will take share while governance-discounted names stay cheap.
• If you need broader sector exposure, hedge life-science tools beta by trimming SLP-adjacent small caps and favoring larger, cleaner balance-sheet names; cover the hedge only after a clean auditor resolution and stabilizing bookings.